SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77502.12
579.48 (0.75%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
91	Astrazeneca Pharma India Ltd.	Q V PT	20,541 Small Cap	8,235.90 (0.24%)	109.8	23.59	15.59	20.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
92	Piramal Pharma Ltd.	Q V PT	22,440 Small Cap	168.20 (-0.21%)	31.99	2.75	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
93	Rubicon Research Ltd.	Q V+ PT	22,613 Small Cap	1,374.55 (0.53%)	120.81	16.8	32.49	25.95	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
94	Neuland Laboratories Ltd.	Q V+ PT	24,097 Small Cap	18,982.30 (1.07%)	67.07	13.06	14.13	64.99	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
95	Sai Life Sciences Ltd.	Q V+ PT	26,385 Small Cap	1,238.15 (-0.38%)	76.97	10.48	17.75	11.20	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
96	Dr. Lal Pathlabs Ltd.	Q V PT	27,195 Small Cap	1,652.20 (1.85%)	54.5	11.51	13.05	17.70	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
97	Acutaas Chemicals Ltd.	Q V+ PT	29,259 Small Cap	3,690.15 (3.26%)	82.51	18.11	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
98	Wockhardt Ltd.	Q V+ PT	31,869 Small Cap	1,948.40 (-0.66%)	148.64	6.41	1.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
99	Krishna Institute of Medical Sciences Ltd	Q V PT	34,892 Small Cap	835.65 (0.59%)	134.63	8.93	11.87	17.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
100	Emcure Pharmaceuticals Ltd.	Q V PT	34,707 Small Cap	1,854.60 (1.36%)	47.99	9.48	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
101	Global Health Ltd.	Q V PT	35,695 Small Cap	1,345.50 (1.35%)	72.91	9	16.83	34.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
102	JB Chemicals & Pharmaceuticals Ltd.	Q V+ PT	36,871 Small Cap	2,318.45 (0.96%)	55.22	9.22	15.51	9.89	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
103	Gland Pharma Ltd.	Q V PT	40,632 Small Cap	2,445.50 (-0.72%)	31.04	3.73	9.35	7.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
104	Narayana Hrudayalaya Ltd.	Q V PT	40,020 Mid Cap	1,985.25 (1.38%)	50.36	8.94	11.88	45.85	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
105	Glaxosmithkline Pharmaceuticals Ltd.	Q V PT	41,731 Mid Cap	2,415.95 (-1.93%)	39.51	17.93	5.49	17.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
106	Aster DM Healthcare Ltd.	Q V+ PT	40,198 Mid Cap	790.60 (1.90%)	105.54	8.95	-13.71	0.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
107	Ajanta Pharma Ltd.	Q V+ PT	41,813 Mid Cap	3,343.80 (-0.09%)	39.56	9.23	13.54	10.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
108	Anthem Biosciences Ltd.	Q V PT	42,995 Mid Cap	771.30 (1.07%)	64.8	13.64	23.81	40.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
109	Ipca Laboratories Ltd.	Q V+ PT	43,040 Mid Cap	1,718.40 (1.29%)	38.5	5.46	8.87	4.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
110	Abbott India Ltd.	Q V PT	54,328 Mid Cap	25,721.65 (0.61%)	35.22	11.45	9.38	18.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
111	Glenmark Pharmaceuticals Ltd.	Q V+ PT	60,890 Mid Cap	2,195 (1.73%)	45.48	5.89	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
112	Alkem Laboratories Ltd.	Q V+ PT	66,524 Mid Cap	5,495.95 (-1.22%)	30.07	4.69	5.71	10.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
113	Biocon Ltd.	Q V PT	68,154 Mid Cap	418.90 (0.17%)	1835.16	2.52	2.44	-9.71	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
114	Fortis Healthcare Ltd.	Q V+ PT	71,593 Mid Cap	974.95 (2.81%)	319.55	7.98	15.55	-22.45	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
115	Laurus Labs Ltd.	Q V+ PT	80,692 Mid Cap	1,525.20 (2.12%)	92.71	15.62	7.19	-2.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
116	Aurobindo Pharma Ltd.	Q V+ PT	89,345 Mid Cap	1,560.05 (0.47%)	37.17	3.95	-3.95	-0.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
117	Mankind Pharma Ltd.	Q V PT	1,02,844 Mid Cap	2,487.40 (-0.11%)	50.42	6.27	14.65	12.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
118	Lupin Ltd.	Q V PT	1,09,576 Mid Cap	2,398.70 (0.09%)	20.57	4.89	8.11	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
119	Zydus Lifesciences Ltd.	Q V PT	1,10,608 Mid Cap	1,099.65 (-0.83%)	21.76	4.22	10.27	30.57	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
120	Max Healthcare Institute Ltd.	Q V+ PT	1,10,950 Mid Cap	1,127.45 (-1.10%)	76.07	10.21	46.01	60.18	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Suven Life Sciences	298.65	8.92%
Themis Medicare	119.15	7.73%
Dishman Carbogen Amc	188	7%
Shilpa Medicare	600.85	5.26%
GPT Healthcare	156.45	4.40%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
KMC Speciality Hosp.	133.60	-5.01%
Morepen Laboratories	59.71	-4.63%
Fischer Medical	39.08	-4.59%
Shree Ganesh Remed.	642.40	-4.38%
Gufic Biosciences	385.40	-2.24%

News about Top Pharma Companies in India

Jul, 2026

Alkem Laboratories informs about newspaper advertisement

Pursuant to Regulation 30 and 47 read alongwith Schedule III of the SEBI LODR Regulations, Alkem Laboratories has informed that it enclosed a copy of advertisement published in today's newspapers, Business Standard (English) and Mumbai Lakshadeep (Marathi) for information regarding 52nd Annual General Meeting of the Company to be held through video conferencing (VC)/ other audio visual means (OAVM). The same is also available on the website of the Company at www.alkemlabs.com.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Dr. Lal PathLabs informs about newspaper publication

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Dr. Lal PathLabs has attached the copy of newspaper advertisement(s), published in Financial Express and Jansatta on July 02, 2026, intimating about the dispatch of Notice of 32nd Annual General Meeting and Annual Report for FY 2025-26 to the Members of the Company.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Ajanta Pharma gets EIR from USFDA for manufacturing facility at Paithan

The cGMP inspection of the Paithan facility was conducted by the USFDA from April 13, 2026 to April 21, 2026

Jul, 2026

Glenmark Pharmaceuticals informs about media release

Glenmark Pharmaceuticals has informed that, Glenmark Specialty S.A, a wholly owned subsidiary of the company (Glenmark) announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody drug conjugate (ADC), for patients with platinum-resistant ovarian cancer (PROC). India will serve as the first country in Glenmark’s licensed markets to initiate patient enrollment for the Phase 3 clinical trial, following the approval of Drugs Controller General of India (DCGI). Glenmark also plans to enroll patients in Australia and South Korea, subject to regulatory approvals. The company has attached media release.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Lupin gets EIR from USFDA for Somerset facility

The inspection was conducted from April 13, 2026, to April 17, 2026

Jul, 2026

Mankind Pharma informs about press release

Mankind Pharma has informed that it enclosed copies of the newspaper advertisement published in ‘Financial Express’ (English) and ‘Jansatta’ (Hindi) on July 1, 2026 regarding 35th Annual General Meeting of the Company scheduled to be held on Tuesday, August 4, 2026 at 03:30 PM (IST) through Video Conferencing / Other AudioVisual Means.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	225 Crore
2	Fabtech Technologies Ltd.	700 Crore
3	Anuh Pharma Ltd.	802 Crore
4	Shree Ganesh Remedies Ltd.	863 Crore
5	Sigachi Industries Ltd.	896 Crore
6	Kopran Ltd.	912 Crore
7	Health X Platform Ltd.	1,009 Crore
8	Wanbury Ltd.	1,007 Crore
9	Gujarat Kidney And Super Speciality Ltd.	1,033 Crore
10	Fermenta Biotech Ltd.	1,043 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,722	54,328	35.00	11.38	23.88	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,663	1,57,093	72.61	18.73	38.24	29.04
Ajanta Pharma Ltd. (M)	Very Good	3,344	41,813	39.60	9.24	26.75	25.35
Lupin Ltd. (M)	Somewhat Good	2,399	1,09,576	20.55	4.88	11.89	20.83
Zydus Lifesciences Ltd. (M)	Very Good	1,100	1,10,608	21.95	4.25	13.46	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,525	80,692	101
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,318	36,871	41.28
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,663	1,57,093	39.25
Aurobindo Pharma Ltd. (M)	Very Good	1,560	89,345	34.75
Ajanta Pharma Ltd. (M)	Very Good	3,344	41,813	31.18
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,318	36,871	54.70	9.13	33.13	15.51
Mankind Pharma Ltd. (M)	Very Good	2,487	1,02,844	50.47	6.27	31.70	14.65
Ajanta Pharma Ltd. (M)	Very Good	3,344	41,813	39.60	9.24	26.75	13.54
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,346	1,11,792	26.64	2.95	14.87	13.26
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,663	1,57,093	72.61	18.73	38.24	11.80

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	1,100	1,10,608	21.95	4.25	13.46	30.57
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,872	4,47,704	39.00	5.36	22.34	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,346	1,11,792	26.64	2.95	14.87	22.29
Abbott India Ltd. (M)	Very Good	25,722	54,328	35.00	11.38	23.88	18.78
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,195	60,890	44.71	5.79	11.86	14.41

You have 7 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Alkem Laboratories informs about newspaper advertisement

Dr. Lal PathLabs informs about newspaper publication

Ajanta Pharma gets EIR from USFDA for manufacturing facility at Paithan

Glenmark Pharmaceuticals informs about media release

Lupin gets EIR from USFDA for Somerset facility

Mankind Pharma informs about press release

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.